[18F]NAV4694
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dementia
Conditions
Dementia, Alzheimer's Disease
Trial Timeline
Jun 1, 2013 → Sep 1, 2018
NCT ID
NCT01886820About [18F]NAV4694
[18F]NAV4694 is a phase 3 stage product being developed by Navidea Biopharmaceuticals for Dementia. The current trial status is unknown. This product is registered under clinical trial identifier NCT01886820. Target conditions include Dementia, Alzheimer's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01886820 | Phase 3 | UNKNOWN |
| NCT01812213 | Phase 2 | Terminated |
| NCT01680588 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 69 |
| AL001 | Alector | Phase 2 | 44 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| IGC AD1 + Placebo | IGC Pharma | Phase 1 | 25 |
| E2020 + Placebo | Eisai | Approved | 85 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Rasagiline | Eisai | Phase 2 | 52 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 23 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo | Eisai | Phase 3 | 77 |
| E2020 + E2020 | Eisai | Phase 2 | 52 |
| donepezil hydrochloride (Aricept) | Eisai | Approved | 85 |
| 3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo | Eisai | Phase 2 | 52 |
| E2020 + E2020 | Eisai | Phase 3 | 77 |
| Irsenontrine + Placebo | Eisai | Phase 2 | 52 |
| E2020 | Eisai | Phase 2 | 52 |
| Mecobalamin | Eisai | Approved | 85 |
| E2020 + Placebo | Eisai | Phase 3 | 77 |
| Donepezil Hydrochloride | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 85 |